Seeking Alpha: Cyclacel on the Verge of Becoming a Competitor for Big Pharma

Cyclacel Pharmaceuticals (CYCC) has been raising the eyebrows of many investors recently. This multi-marketed company has several potential medications in its pipeline, including: a treatment for acute myeloid leukemia in Phase III; a treatment for myelodysplastic syndrome in Phase II; a  treatment for solid tumors in Phase I; and additional candidates in various phases of development. According to the article, Cyclacel Pharmaceuticals is beginning to demonstrate the ability to compete in multiple markets, and is on the verge of proving itself to be a competitor against some of the larger pharmaceutical companies.

View the full article here (

The comments are closed.